Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Price, News & Analysis

Biora Therapeutics logo

About Biora Therapeutics Stock (NASDAQ:BIOR)

Key Stats

Today's Range
N/A
50-Day Range
$0.14
$0.15
52-Week Range
N/A
Volume
16,292 shs
Average Volume
86,634 shs
Market Capitalization
$660 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Biora Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

BIOR MarketRank™: 

Biora Therapeutics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    Biora Therapeutics has a consensus price target of $23.00, representing about ∞ upside from its current price of $0.00.

  • Amount of Analyst Coverage

    Biora Therapeutics has received no research coverage in the past 90 days.

  • Read more about Biora Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Biora Therapeutics are expected to grow in the coming year, from ($12.66) to ($7.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biora Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biora Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for BIOR.
  • Dividend Yield

    Biora Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Biora Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BIOR.
  • Search Interest

    Only 2 people have searched for BIOR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.08% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biora Therapeutics' insider trading history.
Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOR Stock News Headlines

Biora Therapeutics, Inc. (BIOR) - Yahoo Finance
Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
BIORQ Biora Therapeutics, Inc.
Biora Therapeutics, Inc. (BIORQ)
Biora Therapeutics Successfully Completes Restructuring Process
See More Headlines

BIOR Stock Analysis - Frequently Asked Questions

Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.60) earnings per share for the quarter, beating analysts' consensus estimates of ($4.70) by $0.10. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $11.10 million.

Shares of Biora Therapeutics reverse split on Tuesday, January 3rd 2023.The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biora Therapeutics investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Bank of America (BAC) and Ford Motor (F).

Company Calendar

Last Earnings
11/10/2021
Today
10/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BIOR
CIK
1580063
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$23.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.11 million
Net Margins
N/A
Pretax Margin
-4,005.83%
Return on Equity
N/A
Return on Assets
-332.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.05
Quick Ratio
0.05

Sales & Book Value

Annual Sales
$892 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($36.43) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,523,000
Free Float
2,213,000
Market Cap
$660 thousand
Optionable
Optionable
Beta
1.12
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:BIOR) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners